Sth Africa's Litha Healthcare teams with Natco for generics marketing in India

South Africa-based Litha Healthcare Group has signed an exclusive agreement with Indian generic drugmaker Natco Pharma. Under the Group’s newly formed generics business unit, the agreement will include a range of generic pharmaceutical products developed and manufactured by Natco.

Subsidiary Litha Pharma (Pty) will manage the submission and distribution of the products into the South African market and adjacent territories. The range of products includes molecules that have presented challenges to other companies in both the development and intellectual property areas, the company said.

“This agreement enhances the group’s strategy to add to the value and breadth of its generic pharmaceutical pipeline and demonstrates its commitment to an aggressive growth strategy to become a major provider of generic medicines in South Africa. We will continue to seek new and exciting opportunities for the group, through our agreement with Canadian based CPoint Capital, who are a key partner in sourcing and supplying generic product pipelines for our Pharma Division,” says Selwyn Kahanovitz, chief executive of Litha Healthcare.

Mr Kahanovitz added: “Litha’s five year plan is to become the major provider of generic medicines in South Africa; to this end we will continue to aggressively search for licensing agreements of products already registered which can be added to the existing product range and sales network within Litha Pharma.”